Renin-angiotensin-aldosterone system-blocker-induced angioedema
disease diseaseOn this page
Also known as AEACEIRaas-blocker-induced angioedemaRaas-blocker-induced angioneurotic edemaRaas-blocker-induced angioneurotic oedemaRAEreactive angioendotheliomatosisrenin-angiotensin-aldosterone system-blocker-induced angioneurotic edemarenin-angiotensin-aldosterone system-blocker-induced angioneurotic oedema
Summary
Renin-angiotensin-aldosterone system-blocker-induced angioedema (MONDO:0015057) is a disease. A subtype of acquired angioedema — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: Unknown (Worldwide)
- Phenotypes (HPO): 13
Clinical features
Signs & symptoms
Clinical features (HPO)
13 HPO clinical features (Orphanet curated; top 13 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0100665 | Angioedema | Obligate (100%) |
| HP:0000282 | Facial edema | Very frequent (80-99%) |
| HP:0025018 | Abnormal capillary physiology | Very frequent (80-99%) |
| HP:0002098 | Respiratory distress | Frequent (30-79%) |
| HP:0031244 | Swollen lip | Frequent (30-79%) |
| HP:0040315 | Tongue edema | Frequent (30-79%) |
| HP:0100540 | Palpebral edema | Frequent (30-79%) |
| HP:0002781 | Upper airway obstruction | Occasional (5-29%) |
| HP:0010783 | Erythema | Occasional (5-29%) |
| HP:0011855 | Pharyngeal edema | Occasional (5-29%) |
| HP:0012027 | Laryngeal edema | Occasional (5-29%) |
| HP:0000989 | Pruritus | Excluded (0%) |
| HP:0001025 | Urticaria | Excluded (0%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | renin-angiotensin-aldosterone system-blocker-induced angioedema |
| Mondo ID | MONDO:0015057 |
| MeSH | C535293 |
| Orphanet | 100057 |
| SNOMED CT | 403607004 |
| UMLS | C1304495 |
| MedGen | 725846 |
| GARD | 0016936 |
| Is cancer (heuristic) | no |
Also known as: AEACEI · Raas-blocker-induced angioedema · Raas-blocker-induced angioneurotic edema · Raas-blocker-induced angioneurotic oedema · RAE · reactive angioendotheliomatosis · renin-angiotensin-aldosterone system-blocker-induced angioneurotic edema · renin-angiotensin-aldosterone system-blocker-induced angioneurotic oedema
Disease family
This is a subtype of acquired angioedema. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › urticaria › angioedema › acquired angioedema › renin-angiotensin-aldosterone system-blocker-induced angioedema
Related subtypes (4): acquired angioedema type 2, acquired angioedema type 1, acquired angioedema with C1Inh deficiency, vibratory angioedema
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.